These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 26311525)

  • 1. Exploring the role of interleukin-22 in neurological and autoimmune disorders.
    Xin N; Namaka MP; Dou C; Zhang Y
    Int Immunopharmacol; 2015 Oct; 28(2):1076-83. PubMed ID: 26311525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging role of interleukin-22 in autoimmune diseases.
    Pan HF; Li XP; Zheng SG; Ye DQ
    Cytokine Growth Factor Rev; 2013 Feb; 24(1):51-7. PubMed ID: 22906768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting IL-10 in auto-immune diseases.
    Tian G; Li JL; Wang DG; Zhou D
    Cell Biochem Biophys; 2014 Sep; 70(1):37-49. PubMed ID: 24639111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of IL-17 and IL-22 in autoimmunity and cancer.
    Blake SJ; Teng MW
    Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():41-50. PubMed ID: 25398491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-19, IL-20 and IL-24: potential therapeutic targets for autoimmune diseases.
    Leng RX; Pan HF; Tao JH; Ye DQ
    Expert Opin Ther Targets; 2011 Feb; 15(2):119-26. PubMed ID: 21073280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Th17 cells in autoimmune diseases.
    Yang J; Sundrud MS; Skepner J; Yamagata T
    Trends Pharmacol Sci; 2014 Oct; 35(10):493-500. PubMed ID: 25131183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies.
    Maddur MS; Miossec P; Kaveri SV; Bayry J
    Am J Pathol; 2012 Jul; 181(1):8-18. PubMed ID: 22640807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are Th17 cells and their cytokines a therapeutic target in Guillain-Barré syndrome?
    Wu X; Wang J; Liu K; Zhu J; Zhang HL
    Expert Opin Ther Targets; 2016; 20(2):209-22. PubMed ID: 26357850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
    Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
    Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-21 is a central memory T cell-associated cytokine that inhibits the generation of pathogenic Th1/17 effector cells.
    Kastirr I; Maglie S; Paroni M; Alfen JS; Nizzoli G; Sugliano E; Crosti MC; Moro M; Steckel B; Steinfelder S; Stölzel K; Romagnani C; Botti F; Caprioli F; Pagani M; Abrignani S; Geginat J
    J Immunol; 2014 Oct; 193(7):3322-31. PubMed ID: 25172491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Th17 Effector Cytokines for the Treatment of Autoimmune Diseases.
    Yamagata T; Skepner J; Yang J
    Arch Immunol Ther Exp (Warsz); 2015 Dec; 63(6):405-14. PubMed ID: 26358867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Th17 cells in autoimmune diseases.
    Han L; Yang J; Wang X; Li D; Lv L; Li B
    Front Med; 2015 Mar; 9(1):10-9. PubMed ID: 25652649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitigated Tregs and augmented Th17 cells and cytokines are associated with severity of experimental autoimmune neuritis.
    Wang X; Zheng XY; Ma C; Wang XK; Wu J; Adem A; Zhu J; Zhang HL
    Scand J Immunol; 2014 Sep; 80(3):180-90. PubMed ID: 24910360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the Th17 cytokines IL-17 and IL-22 in Rheumatoid Arthritis pathogenesis and developments in cytokine immunotherapy.
    Roeleveld DM; Koenders MI
    Cytokine; 2015 Jul; 74(1):101-7. PubMed ID: 25466295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential.
    Zhu S; Qian Y
    Clin Sci (Lond); 2012 Jun; 122(11):487-511. PubMed ID: 22324470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Th17 pathway as a therapeutic target in rheumatoid arthritis and other autoimmune and inflammatory disorders.
    Roeleveld DM; van Nieuwenhuijze AE; van den Berg WB; Koenders MI
    BioDrugs; 2013 Oct; 27(5):439-52. PubMed ID: 23620106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-35: a Potential Therapeutic Agent for Autoimmune Diseases.
    Guan SY; Leng RX; Khan MI; Qureshi H; Li XP; Ye DQ; Pan HF
    Inflammation; 2017 Feb; 40(1):303-310. PubMed ID: 27696334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Th9 cells and IL-9 in autoimmune disorders: Pathogenesis and therapeutic potentials.
    Deng Y; Wang Z; Chang C; Lu L; Lau CS; Lu Q
    Hum Immunol; 2017 Feb; 78(2):120-128. PubMed ID: 28040536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-38: A New Player in Inflammatory Autoimmune Disorders.
    Xie L; Huang Z; Li H; Liu X; Zheng S; Su W
    Biomolecules; 2019 Aug; 9(8):. PubMed ID: 31387327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered Th17 cells and Th17/regulatory T-cell ratios indicate the subsequent conversion from undifferentiated connective tissue disease to definitive systemic autoimmune disorders.
    Szodoray P; Nakken B; Barath S; Csipo I; Nagy G; El-Hage F; Osnes LT; Szegedi G; Bodolay E
    Hum Immunol; 2013 Dec; 74(12):1510-8. PubMed ID: 23974054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.